Previous 10 | Next 10 |
Athersys (NASDAQ: ATHX ) and University Hospitals Cleveland Medical Center (UH Cleveland) announce that latter is now open as the first clinical site for the MACOVIA (MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome) trial. More news on: Athersys, Inc., H...
University Hospitals Cleveland Medical Center, a nationally ranked hospital, is ready to start screening patients Athersys, Inc. (NASDAQ: ATHX) and University Hospitals Cleveland Medical Center (UH Cleveland) announced today that UH Cleveland is now open as the first clinical sit...
Athersys, Inc. (NASDAQ: ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the Bank of America Merrill Lynch 2020 Virtual Healthcare Conference to investors and analysts. The presentation is scheduled for Thursday, May 14, 2020 at 8...
Medical professionals would surely welcome any safe and effective treatment option for people with COVID-19 -- and pharmaceutical companies are doing their best to hastily find solutions. Preclinical and clinical trials now under way are testing seemingly every plausible hypothesis, from failed ...
Athersys (NASDAQ: ATHX ) initiated with Outperform rating and $14 (528% upside) price target at SMBC Nikko. More news on: Athersys, Inc., Livongo Health, Inc., Pfenex Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the closing of its previously announced underwritten public offering of 25,587,500 shares of its common stock, par value $0.001 per share (Common Stock), at a price to the public of $2.25 per share, which includes 3,337,500 shares of Co...
Athersys is a late-stage biotechnology company developing their stem cell product MultiStem for multiple critical care indications. At present, they have two programs in late-stage development, ischemic stroke and acute respiratory distress syndrome ((ARDS)). Their partner in Japan, Healios,...
Gainers: MoSys (NASDAQ: MOSY ) +100% . More news on: MoSys, Inc., Liberty TripAdvisor Holdings, Inc., Arcus Biosciences, Inc., Stocks on the move, , Read more ...
Shares of Athersys (NASDAQ: ATHX) tumbled nearly 28% today after the company announced the pricing of a public offering of common stock. The development-stage drug company will offer up to 25.6 million shares of common stock at $2.25 per share. If all shares are purchased, then the business ...
Diamond Offshore Drilling (NYSE: DO ) -35% after skipping interest payment. More news on: Diamond Offshore Drilling, Inc., Athersys, Inc., InVivo Therapeutics Holdings Corp., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...